<--- Back to Details
First PageDocument Content
Peptide hormones / Thyroid / Liraglutide / Anti-diabetic medication / Metformin / Medullary thyroid cancer / Novo Nordisk / Rosiglitazone / Sulfonylurea / Diabetes management / Calcitonin / Glimepiride
Date: 2010-01-26 07:06:39
Peptide hormones
Thyroid
Liraglutide
Anti-diabetic medication
Metformin
Medullary thyroid cancer
Novo Nordisk
Rosiglitazone
Sulfonylurea
Diabetes management
Calcitonin
Glimepiride

Victoza (liraglutide [rDNA origin] injection

Add to Reading List

Source URL: www.accessdata.fda.gov

Download Document from Source Website

File Size: 273,22 KB

Share Document on Facebook

Similar Documents

EMDAC Background document Victoza (liraglutide) - LEADER FDA Briefing Document Endocrinologic and Metabolic Drugs Advisory Committee Meeting (EMDAC)

DocID: 1ts1R - View Document

Peptide hormones / Thyroid / Liraglutide / Anti-diabetic medication / Metformin / Medullary thyroid cancer / Novo Nordisk / Rosiglitazone / Sulfonylurea / Diabetes management / Calcitonin / Glimepiride

Victoza (liraglutide [rDNA origin] injection

DocID: 1nE7h - View Document

Chemistry / Liraglutide / Exenatide / Anti-diabetic medication / European Federation of Pharmaceutical Industries and Associations / Innovation / Organisation for Economic Co-operation and Development / Denmark / Magnesium in biology / Anti-diabetic drugs / Europe / Endocrine system

Access to medicines - time for a progressive model Richard Bergström, EFPIA Director General 1

DocID: 1aTpx - View Document

Obesity / Nutrition / Anti-diabetic drugs / Bariatrics / Liraglutide / Bariatric surgery / Diabetes mellitus / Anti-diabetic medication / Very-low-calorie diet / Medicine / Health / Diabetes

PDF Document

DocID: 16ope - View Document

Diabetes / Peptide hormones / Biology / Eli Lilly and Company / Pancreatic hormones / Liraglutide / Incretin / Glucagon-like peptide-1 / Anti-diabetic medication / Endocrine system / Medicine / Anti-diabetic drugs

12933_2015_206_Article 1..11

DocID: 15UUB - View Document